This case was reported in a literature article and described the occurrence of guillain barre syndrome in a 67-year-old male patient who received Flu unspecified (Influenza vaccine) for prophylaxis. The patient's past medical history included gastroesophageal reflux disease. Concurrent medical conditions included hypertension, hyperlipidemia and emphysema. On an unknown date, the patient received Influenza vaccine at an unknown dose. On an unknown date, 14 days after receiving Influenza vaccine, the patient experienced guillain barre syndrome (serious criteria hospitalization and GSK medically significant), demyelinating polyneuropathy (serious criteria hospitalization and GSK medically significant), abdominal distension (serious criteria hospitalization), tingling sensation (serious criteria hospitalization), weakness in extremity (serious criteria hospitalization), areflexia (serious criteria hospitalization), ataxia (serious criteria hospitalization), weakness generalized (serious criteria hospitalization) and respiratory muscle weakness (serious criteria hospitalization). The patient was treated with immunoglobulins nos (Immunoglobulins). On an unknown date, the outcome of the guillain barre syndrome, demyelinating polyneuropathy, abdominal distension, tingling sensation, weakness in extremity, areflexia, ataxia, weakness generalized and respiratory muscle weakness were unknown.  The reporter considered the guillain barre syndrome, demyelinating polyneuropathy, abdominal distension, tingling sensation, weakness in extremity, areflexia, ataxia, weakness generalized and respiratory muscle weakness to be related to Influenza vaccine. Additional information was provided. This case was reported in a literature article and described the occurrence of Guillain-Barre Syndrome (GBS) in a 67-year-old male who was vaccinated with unspecified influenza vaccine (manufacturer unknown) for prophylaxis. The patient had a history of hypertension, hyperlipidaemia, emphysema, and gastroesophageal reflux. disease. No information on patient's family history or concomitant medication was provided. On an unspecified date, the patient received unspecified influenza vaccine (administration route and site unspecified, dosage unknown; batch number not provided). The age of the vaccination was not provided. The patient was 66 or 67-years of age at the time of vaccination. On an unspecified date, 2 weeks after vaccination, the patient developed abdominal distention and tingling sensation of all extremities. Next day, the patient presented to the hospital with above symptoms and hospitalised. Initial physical examination demonstrated diminished motor strength in all extremities and areflexia, with subsequent ataxia and generalized weakness. The patient developed respiratory muscle weakness requiring endotracheal intubation. Laboratory evaluation was unremarkable as the head computed tomography (CT) scan. Cerebrospinal Fluid (CSF) analysis failed to reveal albumin cytologic dissociation or infectious process. An electromyography was suggestive of acute demyelinating polyneuropathy. Subsequently, the patient was diagnosed with GBS. The intravenous immunoglobulins (IVIGs) treatment was started. Despite receiving intravenous immunoglobulins (IVIGs) for 5 days, the patient failed to wean from mechanical ventilation and a tracheostomy was performed, along with a percutaneous endoscopic gastrostomy. Two courses of IVIGs and one course of plasmapheresis were administered which led to weaning of mechanical ventilation and improvement of motor function. The patient was discharged on physical rehabilitation. This case has been considered serious due to hospitalisation. The author commented, "The only risk factor identified was the administration of influenza vaccine two weeks prior to admission." The author concluded "Development of GBS is a potential complication of the Influenza vaccine. It is important to raise awareness of the diverse side effects associated with vaccines. This case demonstrates that early identification and acute critical care management of vaccine-related complications can positively influence patient's outcome."  Lab Comments: Lab testa were performed on unspecified dates. Initial physical examination demonstrated diminished motor strength in all extremities and areflexia, with subsequent ataxia and generalized weakness. The patient developed respiratory muscle weakness requiring endotracheal intubation.Laboratory evaluation was unremarkable as the head computed tomography (CT) scan. Cerebrospinal Fluid (CSF) analysis failed to reveal albumin cytologic dissociation or infectious process. An electromyography was suggestive of acute demyelinating polyneuropathy.